Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal BP-GMC ointment for birch-related pollen-food allergy syndrome
jRCTs031250401Active, not recruiting
- Sponsor
- Wako Filter Technology
- Start
- Oct 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of birch pollen-galactomannan conjugate in Pollen Food Allergy Syndrome (PFAS) (3 arms), sponsored by Wako Filter Technology. Primary endpoint: Asymptomatic intake of 64 g raw apple in Part A. Started Oct 2025; status: active, not recruiting.
02
Drugs
birch pollen-galactomannan conjugate
03
Conditions
Pollen Food Allergy Syndrome (PFAS)
Beyond the preview
Go deeper on jRCTs031250401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250401.